Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acuity Pharmaceuticals
Drug firm closes $15M financing, initiates trial of RNAi therapeutic
November 6th, 2004
Acuity Pharmaceuticals, a product-focused ophthalmic pharmaceutical company, announced the closing of a $15 million Series B financing. Acuity also announced it has initiated a phase I clinical trial of its lead compound Cand5 in patients with age-related macular degeneration (AMD). This is the first time that humans will be dosed with a therapeutic based on the pioneering new technology of RNA interference (RNAi), a recently-discovered biological method of turning off specific disease-causing genes. Acuity is harnessing the potential of RNAi technology to develop novel drugs to treat diseases of the retina such as AMD, which afflicts more than one...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
